CRX 150

Drug Profile

CRX 150

Alternative Names: Amoxapine/dipyridamole; CRx-150; Dipyridamole/amoxapine

Latest Information Update: 02 Jul 2007

Price : $50

At a glance

  • Originator CombinatoRx
  • Class Anti-inflammatories; Anti-ischaemics; Antiplatelets; Antirheumatics; Chemoprotectants; Dibenzoxazepines; Ischaemic heart disorder therapies; Piperazines; Pyrimidines; Tricyclic antidepressants; Vasodilators
  • Mechanism of Action Cytokine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Periodontal disorders; Rheumatoid arthritis

Most Recent Events

  • 02 Jul 2007 Interim results from a phase II clinical trial in patients with rheumatoid arthritis added to the adverse events and Rheumatic Disease therapeutic trials sections
  • 29 Jun 2007 Discontinued - Phase-II for Rheumatoid arthritis in Norway (PO)
  • 29 Jun 2007 Discontinued - Phase-II for Rheumatoid arthritis in Estonia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top